Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma.

@article{Morris2004OutcomesAA,
  title={Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma.},
  author={Emma Morris and Kirsty J Thomson and Charles G. Craddock and Prem Mahendra and Donald J. Milligan and Gordon Cook and Graeme Murray Smith and Anne Parker and Steve A. Schey and Rajesh K. Chopra and Christopher S Hatton and Jane Tighe and A. Hunter and Karl S. Peggs and David Christopher Linch and Anthony Goldstone and Stephen Mackinnon},
  journal={Blood},
  year={2004},
  volume={104 13},
  pages={3865-71}
}
We report the outcomes after reduced-intensity conditioning allogeneic stem cell transplantation (RIT) for non-Hodgkin lymphoma (NHL) in 88 patients (low-grade NHL [LG-NHL], n = 41; high-grade NHL [HG-NHL], n = 37; mantle cell lymphoma [MCL], n = 10). Thirty-seven patients had previously received autografts, and 21 were in complete remission (CR) at transplantation. Conditioning therapy consisted of alemtuzumab, fludarabine, and melphalan. Sixty-five patients received peripheral blood stem… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 121 extracted citations

Favorable overall survival with fully myeloablative allogeneic stem cell transplantation for follicular lymphoma.

Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation • 2008
View 11 Excerpts
Highly Influenced

References

Publications referenced by this paper.
Showing 1-10 of 28 references

Nonablative allogeneic stem-cell transplantation for advanced/recurrent mantle-cell lymphoma.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology • 2003

Similar Papers

Loading similar papers…